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Abstract
Background: The liver has the remarkable capacity to regenerate in order to compensate for lost or damaged
hepatic tissue. However, pre-existing pathological abnormalities, such as hepatic steatosis (HS), inhibits the endogenous
regenerative process, becoming an obstacle for liver surgery and living donor transplantation.
Recent evidence indicates that multipotent mesenchymal stromal cells (MSCs) administration can improve hepatic
function and increase the potential for liver regeneration in patients with liver damage. Since HS is the most common
form of chronic hepatic illness, in this study we evaluated the role of MSCs in liver regeneration in an animal model of
severe HS with impaired liver regeneration.
Methods: C57BL/6 mice were fed with a regular diet (normal mice) or with a high-fat diet (obese mice) to induce HS.
After 30 weeks of diet exposure, 70% hepatectomy (Hpx) was performed and normal and obese mice were divided
into two groups that received 5 × 105 MSCs or vehicle via the tail vein immediately after Hpx.
Results: We confirmed a significant inhibition of hepatic regeneration when liver steatosis was present, while the
hepatic regenerative response was promoted by infusion of MSCs. Specifically, MSC administration improved the
hepatocyte proliferative response, PCNA-labeling index, DNA synthesis, liver function, and also reduced the number of
apoptotic hepatocytes.
These effects may be associated to the paracrine secretion of trophic factors by MSCs and the hepatic upregulation of
key cytokines and growth factors relevant for cell proliferation, which ultimately improves the survival rate of the mice.
Conclusions: MSCs represent a promising therapeutic strategy to improve liver regeneration in patients with HS as
well as for increasing the number of donor organs available for transplantation.
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Background
Under normal conditions, the liver has a remarkable
capacity to regenerate in order to compensate for lost or
damaged hepatic tissue, a process that enables partial
hepatectomy (Hpx) and living donor liver transplant-
ation [1, 2].
Liver regeneration depends mainly on the proliferation
of hepatocytes, which are quiescent under basal condi-
tions, but maintain a unique and powerful ability to pro-
liferate after hepatic resection or injury. Cytokines and
growth factors mediate the priming of hepatocytes and
promote the re-entry into the cell cycle within 24–48
hours post-Hpx. This process also triggers the induction
of cell signaling that has been shown to be part of the
activation of a highly orchestrated gene expression
program responsible for the stepwise organization of
extracellular matrix (ECM), cell proliferation, and liver
growth [1, 2].
In the simplest model, each hepatocyte is expected to
divide about 1.6 times after 70% Hpx, however, entry
into the S phase does not necessarily mean the cell will
complete its division [3]. Adult liver has many binuclear
hepatocytes and their number decreases during the re-
generative process [4, 5].
It must also be considered that for the successful initi-
ation and completion of liver regeneration after Hpx, it
is necessary that the remaining cells within the liver
acquire sufficient substrate to support the metabolic de-
mand for rapid proliferation [6].
Although improved perioperative care and surgical
techniques allow more extended liver resections [7], pre-
existing pathological abnormalities such as liver steatosis
may significantly deteriorate the post-operative course
after Hpx, becoming an impediment for liver surgery
and living donor transplantation [3, 8–15].
For example, the mortality of Hpx patients with mode-
rate to severe steatosis exceeds 10%, whereas the one for
non-fatty liver patients is below 2% [8, 15]. Livers with
more than 30% steatosis are often not used for trans-
plantation due to an increased risk of primary non-
function [11, 16, 17]. This represents a significant waste
of organs, further increasing the already serious shortage
of donor organs available for transplantation.
Due to the increment in prevalence of hepatic steato-
sis accompanied by clinical conditions like hepatocel-
lular carcinoma, which requires surgical resection or
liver transplantation, there is a persistent need for
therapies that can improve post-operative liver func-
tion and regeneration.
Multipotent mesenchymal stromal cells, also referred
as mesenchymal stem cells (MSCs), are a population of
self-renewable and undifferentiated cells present in the
bone marrow and other mesenchymal tissues of adult
individuals [18].
Diverse studies have described the potential role of
MSCs to promote liver regeneration after toxic injury and
some clinical trials have showed that infusion of MSCs
benefits patients with end-stage liver diseases [19–22].
The mechanisms responsible for these therapeutic effects
are not completely understood [23–25]. It has been sug-
gested that MSCs may engraft into the liver and transdif-
ferentiate into hepatocytes or fuse with them [23, 24].
However, the current paradigm is that MSCs support resi-
dent progenitor cells via paracrine mechanisms [26–30].
MSC therapy has been shown to enhance hepatic
regeneration following liver Hpx [31–34], however, the
effect of this therapy following liver resection in an
animal model of impaired hepatic regeneration, like se-
vere steatosis, has not been investigated yet.
In this study we evaluated the role of MSCs in liver re-
generation in an animal model of normal and impaired
liver regeneration.
One of the oldest and most commonly used rodent
models of liver regeneration is 70% Hpx, in which two
thirds of the liver are surgically removed [35, 36]. One ad-
vantage of this model over others is the absence of injury to
the remnant liver tissue following the regenerative stimulus
(surgically induced), which thereby minimizes potential
confounders for the interpretation of the functional specifi-
city of induced signals for the regenerative response itself.
In this study we confirmed a significant inhibition of
hepatic regeneration when liver steatosis was present,
while the hepatic regenerative response was improved by
infusion of MSCs. Specifically, MSCs restored the hepato-
cyte proliferative response and liver function. Further-
more, their infusion reduced apoptosis of hepatocytes,
which ultimately improved the survival rate of the mice.
Methods
Animals and surgical procedures
Male C57BL/6 mice were housed at a constant temperature
(22 ± 2 °C) and 60% relative humidity, with 12:12-hour
light-dark cycle. Five-week-old mice were fed with a
standard diet (normal group; 10 cal% fat, 20 cal% proteins,
and 70 cal% carbohydrates) or high-fat diet (HFD) (obese
group; 60 cal% fat, 20 cal% proteins, and 20 cal% carbohy-
drates – D12492 Research Diets Inc., New Brunswick, NJ,
USA for 30 weeks. At this time, 70% Hpx was performed as
previously described by Higgins and Anderson [36]. Nor-
mal and obese mice were divided into two groups that re-
ceived 5 × 105 MSCs (Hpx +MSCs) or vehicle (Hpx +Vh)
via the tail vein immediately after Hpx. Body weight, food
intake and survival rate were monitored daily, and mice
were sacrificed pre-, 2 and 7 days post-Hpx. When re-
quired, animals were anesthetized with sevofluorane
(Abbot Laboratories, Chicago, IL, USA). Blood samples
were centrifuged, supernatant plasma was collected and
finally stored at -80 °C. The livers were excised,
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weighed, and preserved for subsequent molecular and
histological analysis.
Animal protocols were approved by the Ethics
Committee of the Facultad de Medicina Clínica Alemana -
Universidad del Desarrollo.
MSC and MSCGFP isolation, ex vivo expansion and
characterization
Six- to eight-week-old C57BL/6 or C57BL/6-Tg ACTB-
EGFP 1Osb mice were used as donors of MSCs or
MSCsGFP respectively. They were sacrificed by cervical dis-
location and bone marrow cells were obtained by flushing
femurs and tibias with sterile PBS. After centrifugation,
cells were resuspended in alpha-MEM (Gibco, Waltham,
MA, USA) supplemented with 10% selected fetal bovine
serum (Hyclone, South Logan, UT, USA) and 80 μg/mL
gentamicin (Sanderson Laboratory, Santiago, Chile), and
plated at a density of 1 × 106 nucleated cells per square
centimeter. Non-adherent cells were removed after
72 hours by media change. When foci reached confluence,
adherent cells were detached with 0.25% trypsin, 2.65 mM
EDTA, centrifuged, and sub-cultured at 7000 cells per
square centimeter. After two subcultures, adherent cells
were characterized according to their adipogenic and
osteogenic differentiation potential, as previously described
[37, 38]. Briefly, to induce adipogenic differentiation, con-
fluent adherent cells were cultured in alpha-MEM, supple-
mented with 1 μM dexametasone (Sigma-Aldrich, St.
Louis, MO, USA), 100 μg/mL 3-isobutyl-1-meth-
ylxanthine (Calbiochem, San Diego, CA, USA), 100 μM
indomethacin (Sigma-Aldrich), and 0.2 UI/mL insulin (Eli
Lilly, Indianapolis, IN, USA), replaced every 3 days. After
10 days of stimulation, cell differentiation into lipid-laden
adipocytes was confirmed by Oil Red O staining (Sigma-
Aldrich). To induce osteogenic differentiation, confluent
adherent cells were cultured in alpha-MEM medium
supplemented with 0.1 μM dexamethasone, 10 mM beta-
glycerophosphate (Sigma-Aldrich), and 50 μg/mL ascor-
bate 2-phosphate (Sigma-Aldrich), replaced every 3 days.
After 21 days of stimulation, cell differentiation into
hydroxyapatite-producing osteoblasts was confirmed by
Alizarin Red staining (Sigma-Aldrich). Although there are
currently no consensus markers for murine MSCs as there
exist for human MSCs [39], immunophenotyping was per-
formed by flow cytometry analysis after immunostaining
with monoclonal antibodies against lymphocyte markers
B220, CD4, and CD8-Pe-Cy5 (BD Pharmingen, San
Diego, CA, USA) and putative murine MSC markers
SCA1-APC, CD90-PE, and CD44-PECy5 (eBioscience,
San Diego, CA, USA) (Additional file 1).
MSC or MSCGFP intravenous administration
Slightly anesthetized mice received 5 × 105 MSCs or
MSCsGFP suspended in 0.2 mL of 5% mice plasma
(Hpx +MSCs) or 0.2 mL of 5% mice plasma (Hpx + Vh)
via the tail vein.
Biochemical analysis and liver histology
Serum triglycerides and cholesterol levels were deter-
mined in the Abbot Architect c8000 autoanalyzer. Blood
glucose levels were measured with the glucometer system
Accu-Chek Performance (Roche). Glucose tolerance test
was performed as previously described [40]. To evaluate
liver injury, the levels of serum aspartate aminotransferase
(AST) and alanine aminotransferase (ALT) were measured
via routine clinical chemistry (GOT/AST and GPT/ALT
Wiener Lab, Rosario, Argentina). Serum prothrombin was
measured using the ab157526-Prothrombin mouse ELISA
(Abcam, Cambridge, MA, USA).
Aliquots of frozen liver were assayed for triglyceride and
cholesterol measurements, as previously described [40].
For histologic analysis, serial 3-μm sections of the
right lobes of the liver were stained with hematoxylin
and eosin or Massons’s trichrome to evaluate hepatic
steatosis and liver fibrosis respectively. Under high
magnification of the × 20 objective, 20 consecutive
non-overlapping fields, in each liver, were observed. A
standardized score was employed to evaluate hepatic
steatosis [41]: mild/uncomplicated steatosis (<30% of
hepatocytes affected, without inflammatory component),
moderate (30–60% of hepatocytes affected), and severe
steatosis (>60% of hepatocytes affected).
Hepatic regeneration and apoptosis assay
Three markers of liver regeneration were evaluated:
1. Restitution of the liver weight was determined as the
percentage of regenerated liver mass and calculated
using the following equation: liver mass regeneration
(%) = 100× [C-(A-B)]/A in which A is the estimated
total liver weight at the time of the partial
hepatectomy, B is the weight of the excised liver, and
C is the weight of the regenerated liver [3, 26].
2. Liver samples were stained for proliferating cell
nuclear antigen (PCNA).
After fixation with formalin and paraffin embedding,
4-μm-thick liver sections were evaluated by confocal
microscopy as previously described [40], using
anti-PCNA NB 600-1331, (Novus Biologicals,
Littleton, CO, USA) and anti-rabbit IgG Fab2 Alexa
Fluor 555 (Molecular Probes, Eugene, OR, USA)
antibodies.
3. Liver sections were stained for 5-bromo-2-deoxy-
uridine (BrdU) incorporation. A total of 100 mg/kg
BrdU was injected intraperitoneally 2 hours before
tissue sampling and detected using the BrdU labeling
and detection kit I (Roche, Basel, Switzerland),
according to the manufacturer’s instructions.
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Hepatic apoptosis was assessed by the terminal
deoxynucleotidyl transferase-mediated dUTB-biotin
end-labeling (TUNEL) method using the DeadEnd™
Fluorometric System (Promega, Madison, WI, USA),
according to the manufacturer’s instructions. For all
immunofluorescence studies, the nuclei were counter-
stained with 4′-6′-diamino-2-phenylindole (DAPI) and
fluorescence was evaluated by confocal microscopy
(Fluoview FV10i, Olympus, Tokyo, Japan). Labeling in-
dices were determined by two blinded investigators by
counting PCNA-positive, BrdU-positive and TUNEL-
positive nuclei per 100 hepatocytes in 30 high-power
fields per liver and six livers per experimental group,
using the ImageJ 1.34 software.
Hepatocyte size and binucleation analysis
Because hepatocytes are epithelial cells, their outlines
can be visualized after staining for actin [5]. The size
and proportion of binucleated hepatocytes was evalu-
ated in 4-μm-thick liver sections by confocal micros-
copy, as previously described, using anti-actin sc-1616,
(Santa Cruz Biotechnology, Dallas, TX, USA) and anti-
goat Alexa Fluor 555 A21432, (Invitrogen, Carlsbad,
CA, USA) antibodies. The size and proportion of binu-
cleated hepatocytes were quantitatively assessed in 30
random fields per animal.
Liver gene expression analysis
Expression levels of ACC1, acetyl-CoA oxidase (ACO),
basic fibroblast growth factor (bFGF), carnitine palmi-
toyltransferase I (CPT-1), cytochrome P450, family 2,
subfamily E, polypeptide 1 (CYP2E1), cytochrome P450,
family 4, subfamily a, polypeptide 10 (CYP4a10), cyto-
chrome P450, family 4, subfamily a, polypeptide 14
(CYPa14), epidermal growth factor (EGF), FAT-CD36,
hepatocyte growth factor (HGF), HMG-Coa, insulin
growth factor 1 (IGF-1), interleukin (IL)-1β, IL-4, IL-6,
IL-10, SRBP1a, SRBP-2, tumor necrosis factor alpha
(TNF-α), uncoupling protein 2 (UCP-2) and glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) were
assessed in liver samples by quantitative RT-qPCR, as
described in Additional file 2. The mRNA levels of the
target genes were normalized against the mRNA level of
GAPDH and expressed as fold change versus the normal
pre-hepatectomy (pre-Hpx) group.
Quantification of systemic cytokines and growth factors
Measurements of cytokines (TNF-α, IL-6, IL-1β, IL-4
and IL-10) and growth factors (EGF, HGF, IGF-1 and
bFGF) were assessed in 25 μl of plasma, using the
MCYTOMAG 70 k and MAGPMAG 24 k assay kits
(Luminex, Milliplex MAP, Millipore, Billerica, MA,
USA), respectively, according to the manufacturer’s
instructions. Plates were read on a Luminex 200
(Luminex Corp., Austin, TX, USA) and analyzed with
the Milliplex Analyst software (VigeneTech Inc. Carlisle,
MA, USA).
Analysis of hepatic homing, proliferation and
differentiation of transplanted MSCsGFP
To determine the distribution of MSCsGFP, liver sections
were analyzed by confocal microscopy, as previously de-
scribed [40], using anti-green fluorescent protein (GFP)
sc-5384 (Santa Cruz Biotechnology) and anti-goat Alexa
Fluor 488 A11055 (Invitrogen) antibodies. The relative
percentage of donor MSCGFP in the liver was semi-
quantified by counting GFP(+) cells per 100 nuclei in 30
high-power fields per liver and three animals per experi-
mental group (normal and obese), and experimental
time point (2, 10 and 30 days after Hpx).
To determine if donor cells proliferate in the regener-
ated liver, sections were further stained with anti-PCNA
NB600-1331 (Novus Biologicals, Littleton, CO, USA),
anti-Ki-67 ab15589 (Abcam), and anti-rabbit IgG Fab2
Alexa Fluor 555 #4413S (Cell Signaling, Danvers, MA,
USA) antibodies.
In vitro expanded MSCs and liver sections from normal
and obese animals were evaluated by double-fluorescence
staining to study the phenotype and differentiation of
donor cells in the regenerated liver, using the primary
antibodies: anti-vimentin sc-7557, anti-desmin sc-14026
(Santa Cruz Biotechnology), anti-F4/80 ab74383, anti-
alpha-smooth muscle actin (α-SMA) ab5694 (Abcam) and
anti-albumin NB110-16329 (Novus Biologicals, Littleton,
CO, USA), with secondary antibodies: anti-rabbit IgG
Fab2 Alexa Fluor 488 or 555 (Cell Signaling, Danvers,
MA, USA), anti-goat Alexa Fluor 488 A11055 or 555
A21432 (Invitrogen, Carlsbad, CA, USA).
Co-culture of Hepa 1-6 with MSCs and cell viability
Hepa 1-6 cells (ATCC CRL-1830) were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% selected fetal bovine serum (Hyclone)
and 80 μg/mL gentamicin (Sanderson). To induce fat
overloading of the cells, Hepa 1-6 at 75% confluence
were exposed to different concentrations (0.5 mM,
1 mM and 2 mM) of a long-chain mixture of free fatty
acids (FFAs), oleate and palmitate (2:1 ratio). Stock solu-
tions of 50 mM oleate acid (Sigma-Aldrich) and 50 mM
palmitate (Sigma-Aldrich) prepared in DMEM containing
1% bovine serum albumin were conveniently diluted in
culture medium to obtain the desired concentrations.
Cell culturing was divided into four groups: (1)
medium (DMEM without fetal bovine serum), (2) FFAs
0.5 mM, (3) FFAs 1 mM, and (4) FFAs 2 mM. A trans-
well system (0.4 μm pore size, Corning HTS
Transwell-24 well, Corning, Corning, NY, USA), was
used to avoid the contact of the cells with the MSCs.
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2.5 × 105 Hepa 1-6 cells were loaded into the lower
chamber of the well, and 1 × 104 MSCs were added to
the upper chamber. The Hepa 1-6 cells were co-
cultured with MSCs for 48 h, and viability of the Hepa
1-6 cells was evaluated. As a control group, Hepa 1-6
cells were cultured without MSCs and compared with
the co-cultured group (n = 4).
Annexin V-FITC Apoptosis Detection Kit (BMS500FI,
eBioscience) was used to evaluate the viability of Hepa
1-6 cells according to the manufacturer’s instructions.
Briefly, cells were trypsinized and resuspended in their
original culture medium to avoid the loss of apoptotic
and necrotic cells.
Cells were incubated with annexin V-FITC for 20 minutes
at room temperature and propidium iodide (PI) was added
to detect late apoptosis and necrotic cells.
Cells were acquired in a Cyan ADP flow cytometer.
Data were analyzed with Summit v4.3 software and re-
sults are presented as the percentage of living cells,
negative for annexin V and PI.
Statistical analysis
Data are presented as mean ± SEM. To analyze the
statistical significance of intergroup differences, Krustal-
Wallis test was used to compare mean values among all
groups, and Mann-Whitney U test was used to compare
mean values between two groups. p < 0.05 was considered
statistically significant.
Results
As shown in Additional file 3, mice fed with HFD (obese
group) progressively increased their body weight. At
Pre-Hpx, they almost doubled the body weight of mice
in the normal group (46.6 ± 0.9 g vs. 26.8 ± 1.4 g). While
the normal group showed a glucose tolerance test in the
physiological range, mice in the obese group were glu-
cose intolerant. Serum triglycerides and cholesterol,
blood glucose and plasma insulin levels were increased
in the obese group. Severe hepatic steatosis was evi-
denced histologically and biochemically, however, no
sign of liver fibrosis was detected at this time point.
MSC administration increases survival rate post-Hpx in
obese mice, associated to improved liver regeneration
We evaluated the effect of MSC administration on ani-
mal survival after surgery. As is shown in Fig. 1a, Hpx
resulted in death of 35% of obese + Vh animals (2–3 days
post-Hpx), whereas all obese +MSCs mice and all mice
in the normal groups (Hpx + Vh and Hpx +MSCs) sur-
vived until 7 days post-Hpx (which was the day when
the mice were sacrificed).
Body weight alterations following Hpx were moni-
tored as a marker of health fitness (Fig. 1b). Mice in the
obese + Vh group showed a higher weight loss than
mice in the normal + Vh group, however MSC adminis-
tration significantly reduced these changes in both ex-
perimental groups.
Figure 1c shows liver regeneration rates in the four
groups of mice, 2 and 7 days post-Hpx, expressed as per-
centage of liver mass regeneration.
In normal groups, no differences were observed in the
regenerated liver mass at both time points evaluated, in-
dependent of MSC administration.
Two days post-Hpx, the rate of liver mass regeneration
was lower in the obese + Vh group, compared to the
normal group, however, MSC administration increased
the rates up to normal group levels.
MSC administration induces hepatocyte proliferation and
reduces apoptotic rate after 70% hepatectomy
To determine the hepatic proliferative activity, immuno-
fluorescence staining for the proliferation marker PCNA
was performed 2 days post-Hpx. As shown in Fig. 2a
and c, significantly more PCNA (+) nuclei were observed
in the MSC-treated versus vehicle-treated group, irre-
spective if the mice were normal or obese.
To further confirm the proliferation of hepatocytes,
we analyzed DNA synthesis by BrdU staining. In accord-
ance with the previous results, the percentage of BrDu (+)
nuclei was higher in the MSC-treated groups (Fig. 2b, d).
Previous reports have demonstrated that 2 days after
Hpx, hepatocytes are the principal proliferating cells
[26, 34, 42], however, the identity of the proliferating
cells was confirmed by a double immunofluorescence
for albumin and BrDu incorporation (Additional file 4).
It has been reported that hepatocyte death occurs if
the cells are unable to complete the mitotic cycle.
TUNEL assay was used to address whether apoptosis
contributes to the failure in the regeneration of fatty
livers. Mice in the obese group presented an increased
basal apoptotic rate pre-Hpx, which did not decrease in
sections from vehicle-treated obese mice (Fig. 2e, f ).
Whereas, a significant reduction in TUNEL (+) nuclei
was observed after MSC treatment. The determination
of apoptotic cell identity is more difficult, since in the
late apoptotic process detected by TUNEL, cells are ir-
regularly shaped and have lost many of their markers
(Additional file 4). However, the bibliography supports
the notion that hepatocyte are the principal apoptotic
cell type 2 days after Hpx [3, 12, 43]. To confirm our re-
sults, we made an in vitro co-cultured transwell study
that showed that secretion from MSCs have a direct in-
hibitory effect on hepatic cell death (Additional file 5).
These results indicate that obese mice display impaired
hepatocyte proliferation following Hpx, when compared
to mice in the normal group. However, systemic ad-
ministration of MSCs in this model, induces hepato-
cyte proliferation and reduces hepatocellular death.
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To better characterize the regenerative process, the
size and percentage of binuclear hepatocytes were evalu-
ated by confocal microscopy, 7 days post-Hpx. In accord-
ance with previous reports [5, 44], post-Hpx hepatocytes
were larger in mice of the normal and obese groups, irre-
spective of the treatment (Additional file 6). Regarding the
percentage of binuclear hepatocytes, MSC administration
reduces the decrease of binuclear hepatocytes post-Hpx
(Fig. 2g, h).
MSC administration inhibits liver enzyme release and
improves hepatic function after 70% hepatectomy
The levels of liver enzymes release measured in the peri-
pheral blood provide a good estimate of ongoing liver
damage. In normal and obese groups, the levels of AST
and ALT were measured pre-, 2 and 7 days post-Hpx.
Plasma ALT was significantly increased pre-Hpx in the
obese group, indicating basal hepatocellular damage.
We observed an expected increase in the plasmatic
levels of both transaminases in mice of the normal and
obese groups, 2 days post-Hpx. However, the maximum
AST level was reduced significantly in the obese +MSCs
versus the obese + Vh group. Accordingly, ALT plasma
levels were lower in the normal +MSCs and obese +
MSCs groups. Both aminotransferases returned to base-
line levels in plasma 7 days post-Hpx in all experimental
groups (Fig. 3a, b).
Liver function following Hpx was evaluated by measu-
ring prothrombin plasmatic levels. Mice in the obese
group showed a significant decrease in prothrombin
level 2 days post-Hpx, indicative of a significant loss of
hepatic function. However, MSC administration normalized
prothrombin levels 7 days post-Hpx (Fig. 3c). Plasma albu-
min levels showed no remarkable change in all experimen-
tal groups after Hpx (data not shown).
Together, these findings suggest that MSC administra-
tion can prevent the loss of liver function and contribute
at least in part to maintain or enhance early recovery
after Hpx.
Donor MSCsGFP persist and proliferate, but do not
differentiate into resident liver cells after 70%
hepatectomy
One possibility to explain the observed therapeutic effect
observed is that the administered MSCs could home to
the liver and differentiate into hepatocytes or another
liver resident cell type, which in turn could act as sup-
port cell to induce hepatocyte proliferation. To assess
this possibility, we evaluated MSCs distribution and
cellular fate after their administration using MSCsGFP
donor cells. Confocal microscopy analysis of liver sec-
tions from animals of the normal and obese groups, ob-
tained after 2, 10 and 30 days post-Hpx showed a small
(less than 0.3% percent) but constant number of donor
single cells or cell clusters (Fig. 4a), localized in close
proximity to the blood vessels, in the space of Disse
(Additional file 7). Double fluorescence staining for
GFP/PCNA demonstrated proliferation of donor MSCs
at least 30 days after their administration (Fig. 4b).
PCNA expression has been used as a marker of cell
proliferation; however, an increase in PCNA levels may
also be induced by growth factors or as a result of DNA
damage in the absence of cell cycling [45]. The prolifera-
tion of donor MSC was also confirmed by Ki-67 antigen
expression, which is preferentially expressed during
the late G1, S, G2 and M phases of the cell cycle,
whereas resting, non-cycling cells lack Ki-67 expres-
sion (Additional file 8).
To evaluate whether MSCs could differentiate into
liver resident cells, mature hepatocyte (albumin) or
Fig. 1 MSC administration increases survival rate and enhances liver regeneration of obese mice after 70% hepatectomy. Survival rate of mice
and liver regeneration were evaluated in all experimental groups up to 7 days post-surgery. a Kaplan-Meier survival analysis of normal and obese
mice. b Body weight loss post-Hpx of mice receiving vehicle or MSCs. c Liver regeneration represented as an increase in post-operative liver mass
2 and 7 days after surgery. All data are presented as mean ± SEM (n = 10), a p < 0.05 vs. normal + Vh, 2 days post-Hpx; b p < 0.05 vs. obese + Vh,
2 days post-Hpx
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Fig. 2 (See legend on next page.)
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Kupffer cell (F4/80) marker were analyzed in MSCsGFP,
however, they did not express any of these markers at
any of the studied time points (Additional file 9).
Donor MSCs change their phenotype in the recipient liver
Stellate cells (SCs) are located in the space of Disse, have
features of stem/progenitor cells, and have even been
considered as liver MSCs by some authors [46]. According
to their phenotype, SCs can participate in both liver fibro-
sis and regenerative processes [47]. Since MSCs share
many markers with SCs, and since in our study donor
cells were found in the same hepatic niche, we evaluated
by confocal microscopy the immunoreactivity of common
pro-fibrogenic (α-SMA) and pro-regenerative markers
(desmin and vimentin) in ex vivo expanded MSCs, before
their administration, and in vivo, in liver sections 2 days
post-administration.
Immunofluorescence analysis showed that MSCs co-
express α-SMA, desmin, and vimentin in vitro (Fig. 5a, b),
but once administered, MSCs changed their phenotype
and only expressed the pro-regenerative markers desmin
(Fig. 5d), and vimentin (Fig. 5e). None of the donor
MSCsGPF co-expressed GFP together with the pro-fibrotic
marker α-SMA (Fig. 5c).
MSC administration induces hepatic expression of key
genes for hepatocyte proliferation
Diverse studies have shown that IL-6, TNF-α, and IL-1β
are crucial priming factors for hepatocytes to enter the
cell cycle, whereas EGF, HGF, IGF-1 and bFGF are import-
ant in the proliferative phase. In the liver these factors are
produced and released primarily from hepatocytes and
SCs [2, 48].
MSCs are known to produce, both in vitro and in vivo,
a broad range of cytokines and trophic factors associated
with tissue regeneration. To evaluate whether the thera-
peutic effects observed after MSC administration could
be related to the generation of a pro-regenerative micro-
environment, the hepatic expression of several key fac-
tors was evaluated by RT-qPCR.
As expected, hepatic mRNA levels of IL-6, IL-1β, EGF,
and bFGF were increased 2 days after Hpx in the nor-
mal + Vh group, whereas, MSC administration additionally
increased IL-4 and IL-10 expression (Fig. 6a, b). In accord-
ance with the impaired regeneration capacity of the obese
(See figure on previous page.)
Fig. 2 MSC administration enhances proliferation and inhibits apoptosis of liver parenchymal cells after 70% hepatectomy. Cellular proliferation
and apoptosis were analyzed pre- and 2 days post liver resection in all experimental groups. The effect of MSC administration on cell proliferation
was evaluated by PCNA immunoreactivity (Alexa Fluor 555 – red) and BrdU incorporation (Alexa Fluor 488 – green). Effect of MSC administration
on cell apoptosis was determined by TUNEL staining (FITC – green). In both cases the nuclei were counterstained with DAPI (blue). Representative
micrographs of hepatocyte proliferation determined by (a) PCNA labeling, or (b) BrdU incorporation, and apoptosis determined by (e) TUNEL, in
liver tissue are shown (arrows). Quantification of (c) PCNA, (d) BrdU and (f) TUNEL-positive nuclei was made by digital image analysis. The proportion of
mononuclear and binuclear hepatocytes at the end of the regenerative process was evaluated by immunofluorescence 7 days post-Hpx in all experimental
groups. g Staining of outlines of hepatocytes with actin (Alexa Fluor 555 – red) distinguishes mononuclear from binuclear hepatocytes by
confocal microscopy. h Quantification of binuclear hepatocytes by digital image analysis. All data are presented as mean ± SEM for 30 random
fields per animal and six animals per group. a p < 0.05 vs. normal pre-Hpx; b p < 0.05 vs. normal + Vh; c p < 0.05 vs. obese pre-Hpx and d p < 0.05
vs. obese + Vh
Fig. 3 MSC administration reduces liver injury after 70% hepatectomy. Plasmatic levels of hepatocellular damage markers (a) aspartate aminotransferase
and (b) alanine aminotransferase and hepatocyte function (c) prothrombin were determined 2 and 7 days after surgery. All data are presented as
mean ± SEM (n = 8), a p < 0.05 vs. normal pre-Hpx; b p< 0.05 vs. normal + Vh; c p< 0.05 vs. obese pre-Hpx and d p < 0.05 vs. obese + Vh
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group, only IL-6 showed an increased hepatic expres-
sion 2 days post-Hpx. However, MSC administration to
obese mice stimulated the liver expression of TNF-α,
IL-1β, IL-4, EGF, bFGF, and potentiated the expression
of IL-6 (Fig. 6a, b).
Two days post-Hpx the plasmatic levels of the above
factors were also evaluated. Mice in the normal group
presented increased EGF levels, while MSC administra-
tion augmented the plasmatic levels of IL-6, IL-4, IL-10,
and potentiated TNF-α (Fig. 6c, d).
In the obese group an increase in IL-6 and IL-10 was
observed post-Hpx in both, the vehicle- and MSC-treated
groups, however, MSC administration also significantly in-
creased the levels of IL-4, EGF, HGF, and bFGF. These re-
sults imply that the activation of liver regeneration was
enhanced by MSC administration after Hpx.
MSC administration improves hepatic β-oxidation
It has been recognized that the regenerative liver gener-
ates signals that couple fatty acid (FA) release from
Fig. 4 Donor MSCs persist and proliferate in the liver of 70% hepatectomized mice. Normal and obese mice received 5 × 105 MSCsGPF post-Hpx.
Two, 10 and 30 days later, the presence of donor cells was evaluated by GFP immunoreactivity (Alexa Fluor 488 – green), nuclei were counterstained
with DAPI (blue). a Representative micrographs of donor MSCsGFP in the liver parenchyma. MSC proliferation in hepatic tissue was evaluated by PCNA
immunoreactivity (Alexa Fluor 555 – red). b Representative micrographs of MSCsGFP proliferation 30 days after their administration
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peripheral adipose stores to augment hepatic FA uptake,
which promotes hepatic lipogenesis and leads to a rapid
accumulation of intracellular triglycerides (TG) in the
regenerating liver [6]. In the same line, alterations in the
hepatic lipid metabolism may impair the normal liver re-
generation process. For example, it has been observed
that in the regenerating liver, following Hpx, the regene-
ration process depends on fatty acids β-oxidation res-
ponsible for energy production [6].
We evaluated the plasmatic and hepatic cholesterol and
triglyceride content, 2 and 7 days post-Hpx (Additional
file 10). In accordance with previous reports [49, 50], this
analysis showed that the normal mice exhibited a transient
increase in hepatic triglycerides 2 days post-Hpx inde-
pendent of MSC administration (Additional file 10).
The obese groups presented significant steatosis pre-
Hpx, however, we did not find changes in hepatic trigly-
ceride and cholesterol levels post-Hpx (Additional file 10).
Furthermore, the administration of MSC failed to
modify the expression of genes that have been associated
to hepatic adipogenic changes during early liver regener-
ation (Additional file 10).
Finally, we evaluated the hepatic expression of mito-
chondrial and microsomal lipid peroxidation components,
2 days post-Hpx. Administration of MSC increased the
expression of UCP-2 in normal and obese groups versus
vehicle-treated mice, while the hepatic expression of
CYP2E1 in obese Hpx-MSCs shows the same level as pre-
Hpx, the vehicle-treated group showed a significantly
decrease in the CYP2E1 expression (Fig. 7). These results
suggest an improvement in the β-oxidation following
MSC administration.
Discussion
The regenerative potential of the liver is essential for
survival following partial resection and after acute and
Fig. 5 Donor MSCs show a pro-regenerative phenotype when it reaches the liver parenchyma. The in vitro expression of pro-fibrotic (α-SMA) and
pro-regenerative (vimentin and desmin) markers was evaluated in donor MSCs before their administration. Representative micrographs of (a) individual
immunoreactivity for α-SMA (Alexa Fluor 555 – red), vimentin (Alexa Fluor 488 – green) and desmin (Alexa Fluor 488 – green), and (b) co-expression of
these markers. The in vivo expression of α-SMA, vimentin and desmin was evaluated by confocal microscopy in liver sections 2 days post MSCsGFP
administration in normal and obese hepatectomized mice. Representative micrographs of (c) MSCsGFP/α-SMA (Alexa Fluor 488 – green/Alexa Fluor
555 – red), (d) MSCs-GFP/desmin (Alexa Fluor 488 –green/Alexa Fluor 555 – red) and (e) MSCs-GFP/vimentin (Alexa Fluor 488 – green/Alexa Fluor 555 – red)
colocalization. In all cases nuclei were counterstained with DAPI (blue)
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chronic liver injury secondary to toxins or metabolic dis-
eases [2]. However, this potential is inhibited in hepatic
steatosis, a common clinical condition resulting from a
variety of etiologies such as obesity, diabetes mellitus,
and alcohol intoxication [51].
There is a recognized association between chronic
hepatic steatosis and impaired regeneration in experimen-
tal animal models. Diabetic KK-A [52], leptin-resistant
(db/db) [53, 54] and leptin-deficient (ob/ob) [55, 56], high
fat [9] and high fructose [57] diet-fed mice all of which ex-
hibit hepatic steatosis, have all been reported to demon-
strate impeded regeneration after hepatectomy or CCL4
administration.
In contrast to this, liver regeneration is not impaired in
models of mild hepatic steatosis [58, 59], leading some in-
vestigators to postulate that the degree of steatosis is
important in determining its effects on liver regeneration.
Consistent with that interpretation, liver regeneration is
variably affected in animals fed with a methionine
choline-deficient diet, a phenotype dependent on the mag-
nitude of steatosis [6, 12].
For testing the therapeutic effect of MSC administra-
tion, we combined a commonly used animal model of
hepatic steatosis induced by chronic exposure to HFD,
which is the most similar to the human clinical condi-
tion [60], and a widely validated experimental model of
liver regeneration. In this animal model, in which two
thirds of the liver are surgically excised and the residual
liver regrows to restore most of the lost tissue and func-
tion within 5 to 7 days [35, 36, 61].
In accordance with previous reports [9], we showed
that sustained feeding with a HFD resulted in impaired
Fig. 6 MSC administration increases local and systemic levels of key hepatic regenerative inductors, after 70% hepatectomy. Hepatic mRNA levels
of (a) interleukins (TNF-α, IL-6, IL-1β, IL-4, and IL-10) and (b) pro-regenerative trophic factors (EGF, HGF, IGF-1, and bFGF) quantified by RT-qPCR,
2 days after-Hpx. Quantitative analysis of plasmatic levels of the same (c) interleukins and (d) pro-regenerative trophic factors determined by Luminex
Multiplex system, 2 days after-Hpx. All data are presented as mean ± SEM (n = 8), a p < 0.05 vs. normal pre-Hpx; b p < 0.05 vs. normal + Vh; c p < 0.05 vs.
obese pre-Hpx and d p < 0.05 vs. obese + Vh
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liver regeneration. This impairment was associated with
deregulation of many of the specific signaling events
known to be regulated during liver regeneration, leading
to a decreased animal survival rate after Hpx.
Although a number of reports have proven that MSCs
are effective in inducing hepatic regeneration [19–21, 24],
and prevent non-alcoholic steatohepatitis development
[40, 62, 63]. The improvement of hepatic regeneration in
models of severe hepatic steatosis has not been explored.
We found that MSC administration stimulates liver
regeneration in normal mice, and restores this response
in obese mice after Hpx. The therapeutic effects were re-
lated to an in vivo stimulation of hepatocyte prolifera-
tion as indicated by the expression of PCNA and the
incorporation of BrdU, resulting in increased growth of
the remnant liver after Hpx.
Binucleation is another interesting feature of adult
hepatocytes that begins in the neonatal liver [64].
It has been shown that the number of binucleated
hepatocytes decreases during liver regeneration after
Hpx [65]. When liver regeneration is impaired, binuclear
hepatocytes seem to preferentially undergo unconven-
tional cell divisions, in which binuclear mother cells
gather their chromosomes at the center of the cells and
split two nuclei to two daughter cells again [4, 5].
We evaluated the number of nuclei and confirmed
that the proportion of binuclear hepatocytes decreased
during liver regeneration after Hpx. However, these
changes were less pronounced in normal and obese MSC-
treated mice, suggesting a stimulation of hepatocyte pro-
liferation that encourages mononuclear cells to follow the
normal cell division cycle.
The significantly increased level of aminotransferases
in obese untreated mice 2 days post-Hpx, along with
increased apoptotic rates, indicate a vulnerability of the
steatotic liver to surgical insult. Moreover, the finding
that some obese + Vh mice died at this time point after
Hpx suggests that these changes contributed to the poor
outcome.
In spite of the increased susceptibility to liver damage
due to the impaired regeneration, some obese untreated
mice were able to eventually recover from Hpx, with
serum aminotransferases returning to baseline levels
7 days-post Hpx, and with a liver mass similar to that of
normal mice in the later phase of regeneration. In the
clinical setting, however, the early post-operative phase
is of greater importance, as impaired liver function im-
mediately after Hpx makes steatotic livers more prone to
develop liver failure [66, 67]. The present results, also
provide evidence that steatotic livers have a significantly
lower functional capacity during the entire regeneration
process, since at 7 days post-Hpx, plasma prothrombin
levels returned to basal levels only in obese +MSCs
mice.
Both, direct differentiation of MSCs into parenchymal
cells or indirect support to hepatocyte proliferation by
secretion of trophic factors and cytokines, could be re-
lated to their therapeutic effects [68].
In contrast to our results, Boeykens et al. described
that intraportally administered MSCs following Hpx of
steatotic liver does not improve liver regeneration [69].
The differences could be associated to the hepatic stea-
tosis model used in this work, the methionine-choline
deficient (MCD) diet is not comparable to the HFD ex-
posure, since the MCD diet model does not develop in-
sulin resistance, and presents excessive weight and liver
loss, and decreased triglycerides and cholesterol plas-
matic levels, not observed in humans. Another relevant
Fig. 7 MSC administration enhances hepatic expression of UCP-2 after 70% hepatectomy in obese mice. Hepatic mRNA levels of (a) mitochondrial
(CPT-1, CYP2E1, and UCP-2) and (b) microsomal (ACO, CYP4a10, CYP4a14) lipid peroxidation factors; quantified by RT-qPCR, 2 days post-Hpx.
Data are presented as mean ± SEM (n = 8), a p < 0.05 vs. normal pre-Hpx; b p < 0.05 vs. normal + Vh; c p < 0.05 vs. obese pre-Hpx and d p < 0.05
vs. obese + Vh
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difference is the administration of MSCs 1 week after
70% Hpx, when the priming phase of hepatocytes has
occurred.
Here we analyzed the migration of MSCs into the liver
and their differentiation potential not only into hepato-
cytes, but also into macrophages and SCs, since it has
been reported that these cells also participate in the re-
generative process [48]. Donor-derived cells were de-
tected in the space of Disse and proliferated in the liver
of recipients. The fact that MSCs were located in this
space, which has features of stem cell niches [40, 70, 71],
was unexpected, since in other models of tissue injury
MSCs were found near the vasculature [40, 70]. How-
ever, their failure to express albumin suggests that MSC
therapeutic effects involve mechanisms other than en-
graftment into host tissue and differentiation into paren-
chymal cells.
Quiescent SCs are typically located between sinusoidal
endothelial cells and hepatocytes, in the Disse space.
Until recently, SCs were mainly studied regarding their
fibrogenic potential in chronic diseases when they ex-
press α-SMA and acquire a myofibroblastic phenotype
[47]. Conversely, their identity and function in normal
liver has received little attention. In the last years, SCs
have been implicated in assisting liver regeneration.
Specifically, they acquire a pro-regenerative phenotype
characterized by the expression of vimentin [72] and
desmin [73] as well as the production of a wide array of
cytokines and factors that may directly enhance the prolif-
eration of liver progenitor cells and hepatocytes [74–77].
The evaluation of transdifferentiation of donor MSCs
into SCs is complex, since in vitro cultured MSCs ex-
hibit a marker profile similar to SCs, making discrimin-
ation between them more difficult. Moreover, recent
data suggest that SCs represent liver-resident MSCs due
to their potential to differentiate into adipocytes and
osteocytes, and their supportive effects on extramedul-
lary hematopoiesis [46, 78].
We confirmed that in vitro expanded MSCs express α-
SMA, vimentin, and desmin. However, once administered,
donor cells shut down α-SMA expression and maintain a
pro-regenerative phenotype characterized by the expression
of vimentin and desmin. Therefore, MSCs remaining in the
Disse space could continuously deliver therapeutic mole-
cules locally during the entire regenerative progression.
In order to initiate the liver regenerative process, the
hepatocytes must first be “primed” to acquire prolifera-
tive competence by inflammatory cytokines, such as
TNF-α [79] and IL-6 [3, 80], which in turn stimulate the
expression of immediate early genes, enabling the cells
to fully respond to growth factors like HGF, IGF-1, EGF,
and bFGF [48, 81].
MSCs are known to produce and secrete, both in
vitro and in vivo, a broad range of cytokines including
TNF-α [82]. It has been shown that the most “up-
stream” event impairing hepatocyte proliferation in
fatty livers is the release of TNF-α [3, 56]. Another
MSC secreted cytokine, is IL-6 [29, 83], which regulates
the acute-phase response in liver regeneration as well
as the inhibition of hepatocyte apoptosis [84].
In accordance with previous studies [85, 86], we found
another beneficial effect of MSC administration: the in-
creased liver expression of IL-4. This response may pre-
vent adverse effects of the pro-inflammatory cytokine
TNF-α, which is needed for the initiation of liver regene-
ration, but also mediates cell death [87, 88].
In addition to cytokines, several growth factors, in-
cluding bFGF, EGF, and HGF, are secreted by MSCs,
which promote hepatocyte replication and revasculariza-
tion during liver regeneration [89, 90].
Interestingly, the hepatic mRNA levels of TNF-α, IL-6,
EGF, and bFGF, were significantly enhanced 2 days after
Hpx in mice livers of obese MSCs-treated group com-
pared to vehicle-treated animals, and some of these
changes were additionally correlated at plasmatic level.
In the same line, we showed that non-contact co-
culture in transwell caused a significantly protection of
steatotic hepatic cells by MSCs. Protein-array analysis of
the MSC-conditioned medium has revealed more than
150 proteins, most of which are growth factors, cyto-
kines, and chemokines [26, 28]. In addition, extracellular
vesicles, such as microvesicles and exosomes, are pro-
posed as key mediators of information transfer between
different cells for tissue repair [91]. In both cases, several
of the detected molecules have known antiapoptotic and
liver regeneration-stimulating effects [26, 27]. Moreover,
unlike pharmaceutical treatments that deliver a single
agent at a specific dose, MSCs are site-regulated and se-
crete bioactive factors and signals at variable concentra-
tions in response to local microenvironmental cues [92].
We can only speculate what specific mediators present
in the conditioned medium are responsible for the res-
toration of liver regeneration, for example factors such
as HGF, bFGF, nerve growth factor, IL-Ra and IL-10, were
reported to have cytoprotective or anti-inflammatory ef-
fects on hepatocytes [93]. Although, systemic proteomic
analysis combined with fractionation studies of MSC-
conditioned medium is necessary to identify key thera-
peutic components.
A number of experimental observations have suggested
that alterations in systemic and hepatic lipid metabolism,
including increased lipid peroxidation along with impaired
mitochondrial and microsomal β-oxidation of fatty acids,
and a subsequent deficit in ATP, are related to impaired
liver regeneration [6, 94].
In accordance with previous studies in our laboratory
[40], we found that MSC-treated groups show similar hep-
atic expression of CYP2E1, the major enzyme responsible
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for mitochondrial β-oxidation [95], than pre-Hpx groups.
In contrast, the hepatic expression of CYP2E1 decreased
significantly in vehicle-treated groups.
It has been suggested that the induction of CYP2E1 is
an adaptive response to prevent lipid overload. It is sug-
gestive that this result was accompanied by the increased
expression of CYP4a10 and CYP4a14 in all experimental
groups. Like CYP2E1, CYP4a enzymes are fatty acid
hydroxylases, and are co-regulated with other genes that
encode proteins involved in fatty acid β-oxidation, which
in turn are key intermediates in the adaptive response to
an altered hepatic lipid metabolism [95, 96].
In accordance with previous data, we confirmed in-
creased hepatic UCP-2 mRNA levels, 2 days after Hpx
[97, 98], however, MSC administration potentiated this
expression. In the mitochondria, UCP-2 functions as an
uncoupler when it is activated by superoxide and other
metabolites of lipids and proteins [99, 100]. The proton
leak via UCP-2 decreases reactive oxygen species (ROS)
production and protects from oxidative stress [101–103].
In this respect, a significant delay has been described in
the growth of liver remnants after Hpx in mice genetically
deficient in UCP-2 [104].
Our data are not sufficient to establish a functional link
between increased liver regeneration and restoration of key
enzymes of β-oxidation and UCP-2, however, the sequence
of these events and the fact that impaired β-oxidation and
ROS have been shown to activate cell cycle inhibitory pro-
teins [105, 106] make this relationship plausible. Further
studies are needed to test this hypothesis and that issue will
be taken into account in our next study.
Before translating our promising preclinical data, several
practical issues should be addressed, including the best
source of MSCs for transplantation. Autologous MSCs ap-
pear to be the ideal choice because they minimize infec-
tious disease dissemination risk. However, aged MSCs
display senescent features when compared with cells iso-
lated from young donors [107, 108].
Moreover, others and we have shown that chronic
diseases could modify the abundance, the phenotype, or
the potentials of MSCs [109]. In particular, diet-induced
obesity in mice alters the differentiation potential of MSCs
resident in various tissues, including bone marrow. These
effects may be regulated in part by increased levels of
FFAs, but may involve other obesity-associated cytokines
[110, 111]. In the same line, studies have shown that
MSCs isolated from obese human donor have loss of
stemness markers and increased expression of inflamma-
tory cytokines [112, 113].
Thus, allogeneic bone marrow seems to be the ideal
source of MSCs for transplantation in patients with
hepatic steatosis, as in the case in the treatment of pa-
tients with other diseases, where promising results and
no toxicity has been described [114].
Conclusions
In summary, in this study we have shown that severe
liver steatosis resulted in a marked inhibition of hepatic
regeneration after Hpx, and that MSC administration
enhanced, in normal mice, and restored, in obese mice,
the hepatic regeneration process. These effects may be
associated to the acquired pro-regenerative phenotype of
MSCs in vivo and the upregulation of key cytokines and
growth factors for cell proliferation, which ultimately
improves the survival rate of the mice.
The most critical phase in patients undergoing partial
liver resection or transplantation of a partial graft is
during the early post-operative period. Potential new
treatment strategies to enhance or accelerate liver re-
generation should therefore be pointed toward this
early post-operative stage. Therefore, administration of
MSCs represents a promising therapeutic strategy to
improve liver regeneration in patients with steatosis
and to increase the number of donor organs available
for transplantation.
Additional files
Additional file 1: Characterization of bone marrow-derived MSCs isolated
from C57BL/6 adult male mice. Bone marrow cells were cultured in
alpha-MEM containing 10% selected fetal bovine serum into plastic
dishes. Plastic adherent cells were (A) ex vivo expanded and (B)
differentiated into adipogenic or (C) osteogenic lineages. (D) Cells were
also immunophenotyped according to the expression of SCA-1, CD90,
CD44 and no expression of B220, CD4 and CD8 antigens. Data shown are
representative of cells isolated from four different animals. (PDF 232 kb)
Additional file 2: RT-PCR specific primers and characteristics of amplicons.
Gene expression levels in liver samples were assessed by quantitative qRT-
PCR. For this, total RNA was purified using TRIzol (Invitrogen) and quantified
by absorbance at 260 nm. One microgram of total RNA was used for reverse
transcription. Real-time PCR was performed in a final volume of 10 μl
containing 50 ng of cDNA, PCR LightCycler-DNA Master SYBRGreen
reaction mix (Roche), 3 mM MgCl2, and 0.5 μm of each primer, using a
Light-Cycler thermocycler (Roche). To ensure that amplicons were from
mRNA and not from genomic DNA amplification, control without reverse
transcription was included. Amplicons were characterized according to their
size evaluated by agarose gel electrophoresis and to their melting
temperature determined in the LigthCycler thermocycler. Relative
quantification was performed by the method described by Schmitten
et al. [1]. (PDF 220 kb)
Additional file 3: Characterization of biochemical and histological
parameters of mice exposed to HFD. After 30 weeks of exposure to regular
diet (normal), or HFD (obese), several biochemical parameters were
assessed, including: (A) body weight. (B) Glucose tolerance test. (C) Serum
triglycerides and cholesterol, blood glucose, plasma insulin, and triglyceride
content in the liver. At this time, histological analysis of liver (D) H&E and (E)
Masson’s trichrome-stained sections was also performed. Data are presented
as mean ± SEM, n = 15. *p < 0.01 vs. normal. (PDF 522 kb)
Additional file 4: Colocalization of hepatocyte and proliferation or
apoptotic markers in vivo. Hepatocyte proliferation after Hpx was
identified by colocalization of BrDu incorporation (FITC – green) and
albumin (Alexa Fluor 555 – red). Hepatocyte apoptosis after Hpx was
evaluated by colocalization of TUNEL (FITC – green) and albumin. Nuclei
were counterstained with DAPI (blue). Representative micrograph of (A)
proliferation and (B) apoptosis confocal microscopy 2 days after Hpx.
(PDF 275 kb)
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Additional file 5: MSCs improved the viability of fat overloading hepatic
cells. The viability of Hepa 1-6 cells treated with 0.5, 1 or 2 mM of free
fatty acid mixture (2:1 ratio of oleate and palmitate) was evaluated after
48 hours of transwell co-culture with medium (control group) or MSCs
(MSCs group). All data are presented as mean ± SEM (n = 4), *p < 0.05 vs.
control group. (PDF 154 kb)
Additional file 6: The size of the hepatocytes increases after 70%
hepatectomy. The hepatocyte size at the end of the regenerative process
was evaluated by immunofluorescence 7 days post-Hpx in all experimental
groups. Staining of outlines of hepatocytes with actin (Alexa Fluor 555 – red)
distinguishes the cell limits by confocal microscopy. The bar represents the
hepatocyte area quantified by digital image analysis. All data are presented
as mean ± SEM for 30 random fields per animal and six animals per group.
a p < 0.05 vs. normal pre-Hpx; c p < 0.05 vs. obese pre-Hpx. (PDF 213 kb)
Additional file 7: Donor MSCs persist near blood vessels and space of
Disse in the liver of 70% hepatectomized mice. Normal and obese mice
received 5 × 105 MSCsGFP post-Hpx. The presence of donor cells was evaluated
by GFP immunoreactivity (Alexa Fluor 488 – green), nuclei were counterstained
with DAPI (cyan) and blood vessel were identified by phase contrast and
marked by a red dashed line. Representative micrographs of donor MSCsGFP 2
and 30 days after administration. (PDF 383 kb)
Additional file 8: Donor MSCs proliferate in the liver of 70%
hepatectomized mice. Normal and obese mice received 5 × 105 MSCsGPF
post-Hpx. Two, 10 and 30 days later, the proliferation of donor cells was
evaluated by colocalization of GFP (Alexa Fluor 488 – green) and Ki67
immunoreactivity (Alexa Fluor 555 – red). Nuclei were counterstained with
DAPI (blue). Representative micrographs of donor MSCGFP proliferation in
the liver parenchyma 10 days after their administration. (PDF 216 kb)
Additional file 9: Donor MSCs proliferate in the liver of 70%
hepatectomized mice. Normal and obese mice received 5 × 105 MSCsGPF
post-Hpx. Two, 10 and 30 days later, the proliferation of donor cells was
evaluated by colocalization of GFP (Alexa Fluor 488 – green) and Ki67
immunoreactivity (Alexa Fluor 555 – red). Nuclei were counterstained with
DAPI (blue). Representative micrographs of donor MSCGFP proliferation in
the liver parenchyma 10 days after their administration. (PDF 256 kb)
Additional file 10: MSC administration does not change lipid
metabolism after 70% hepatectomy. (A) Serum cholesterol level (B) serum
triglycerides levels, (C) liver cholesterol content and (D) liver triglyceride
content were quantified pre-, 2 and 7 days post-Hpx. Hepatic mRNA
levels of key enzymes involved in (E) cholesterol (SRBP-2 and HMG-COA)
and (F) triglyceride metabolism (Fat-CD36, SRBP-1a and ACC), were quantified
by qRT-PCR, 2 days post-Hpx. Data are presented as mean ± SEM (n = 8),
a p < 0.05 vs. normal pre-Hpx; b p < 0.05 vs. normal + Vh; c p < 0.05 vs. obese
pre-Hpx and d p < 0.05 vs. obese + Vh. (PDF 376 kb)
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